Back to top

Analyst Blog

Zacks Equity Research

CBD Posts Strong 3Q Results

WMT CBD

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Companhia Brasileira de Distribuicao (CBD - Analyst Report) reported third quarter 2012 earnings per share of 69 cents compared with 31 cents in the third quarter of 2011.

The increase reflected the continuing operational improvements in the two business segments, namely GPA Food and Viavarejo.

Quarter in Detail

In the third quarter of 2012, consolidated gross sales, comprising GPA Food and Viavarejo, increased 8.7% (in local currency) driven by same store sales growth owing to improved product mix and addition of new stores. Consolidated net sales climbed 9.7% during the quarter.

Though gross profit climbed 3.9%, gross margin contracted 140 basis points to 26.4% from the prior-year quarter, pressured by increased logistics costs in the electronic segment.

EBITDA (Earnings Before Interest Tax and Depreciation) increased 11.1%, while EBITDA margin expanded 10 basis points year on year to 6.6%, driven by operational improvement at GPA Food.

Segment Details

GPA Food’s gross sales increased 9.5% in the quarter, driven by 6.8% growth in gross same store sales. The 15 new stores added in the quarter also boosted sales of the segment. Net sales in the segment climbed 9.8% year over year.

Viavarejo’s gross sales increased 7.8% in the quarter, driven by 7.5% growth in gross same store sales. Net sales in the segment climbed 9.5% year over year.

Recommendation

We are optimistic about the company’s position in the retail sector. CBD is a leading player in the global food retail sector based on both gross sales and number of stores.

However, it also faces intense competition from its rivals such as Wal-Mart Stores, Inc. (WMT - Analyst Report) and Carrefour SA as well as from local and regional players in respective countries.

Currently, we have a Neutral recommendation on CBD. The stock carries a Zacks #3 Rank (a short-term Hold rating).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%